Lyell Immunopharma earnings were -$210.3M for the trailing 12 months ending Jun 30, 2024, with N/A growth year over year. The latest LYEL earnings report on Jun 30, 2024 announced Q2 2024 earnings of -$45.8M, down 24.5% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, LYEL reported annual earnings of -$234.6M, with 28.1% growth.
What were Lyell Immunopharma's earnings last quarter?
Lyell Immunopharma (NASDAQ: LYEL) reported Q2 2024 earnings per share (EPS) of -$0.18, up 30.77% year over year. Total LYEL earnings for the quarter were -$45.81 million. In the same quarter last year, Lyell Immunopharma's earnings per share (EPS) was -$0.26.
As of the last Lyell Immunopharma earnings report, Lyell Immunopharma is currently losing money. Lyell Immunopharma's net profit (also called net income) for the twelve months ending Jun 30, 2024 was -$210.26 million, a 0.36% increase year over year.
What was LYEL's earnings growth in the past year?
As of Lyell Immunopharma's earnings date in Q4 2024, Lyell Immunopharma's earnings has grown year over year. LYEL earnings in the past year totalled -$210.26 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.